Polycystic Kidney Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – (US)
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the progressive development and enlargement of fluid-filled cysts in the kidneys, accompanied by symptoms such as hypertension. The launch of Otsuka’s Jynarque (tolvaptan), indicated for patients with rapidly progressive forms of the disease, changed the treatment paradigm, and this agent became the first and only disease-modifying therapy approved for ADPKD. Other therapies, such as antihypertensives, are also widely used in ADPKD patients. This longitudinal analysis of claims data provides detailed insight into U.S. prescribing patterns for ADPKD.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line oftherapy in newly diagnosed ADPKD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ADPKD patients?
- How has Jynarque (tolvaptan) been integrated into the treatment algorithm, and what is its source of business?
- What percentage of ADPKD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of ADPKD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates amongdrug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Otsuka, Pfizer, Bausch Health, Merck, Novartis, GlaxoSmithKline’s Coreg CR and others
Key drugs: Jynarque (tolvaptan), ACE inhibitors, ARBs, calcium channel blockers, diuretics, beta-blockers
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
Table of contents
Laia Martínez-Carreres, M.Sc., Ph.D., Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematological Disorders. Dr. Martinez-Carreres has authored reports on polycystic kidney disease, venous thromboembolism, and atrial fibrillation. Prior to joining Clarivate, she was a clinical research project manager at Parc Taulí Hospital (Spain). She holds a Ph.D. in biomedical sciences from the University of Lausanne, where she studied the role of the cell cycle-related protein CDK4 in metabolism in the laboratory of Professor Lluis Fajas. She also holds a master’s degree in translational medicine and a bachelor’s degree in biomedical sciences, both from the University of Barcelona. Dr. Martínez-Carreres also trained as a data analyst at EADA Business School in Spain.